This story was originally posted on Nov. 1.

Affymetrix executives offered more details about the firm's ongoing turnaround during the company's third quarter earnings call last week.

While CEO Frank Witney acknowledged on the call that the Santa Clara, Calif.-based company reported "modest" year-over-year growth of 1 percent in Q3, he said the firm believes that its "growth momentum" will continue, driven by new product offerings.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.